Enhancing reproducibility in cancer drug screening: How do we move forward?

Christos Hatzis, Philippe L. Bedard, Nicolai J. Birkbak, Andrew H. Beck, Hugo J.W.L. Aerts, David F. Stern, Leming Shi, Robert Clarke, John Quackenbush, Benjamin Haibe-Kains

Research output: Contribution to journalReview articlepeer-review

52 Scopus citations

Abstract

Large-scale pharmacogenomic high-throughput screening (HTS) studies hold great potential for generating robust genomic predictors of drug response. Two recent large-scale HTS studies have reported results of such screens, revealing several known and novel drug sensitivities and biomarkers. Subsequent evaluation, however, found only moderate interlaboratory concordance in the drug response phenotypes, possibly due to differences in the experimental protocols used in the two studies. This highlights the need for community-wide implementation of standardized assays for measuring drug response phenotypes so that the full potential of HTS is realized. We suggest that the path forward is to establish best practices and standardization of the critical steps in these assays through a collective effort to ensure that the data produced from large-scale screens would not only be of high intrastudy consistency, so that they could be replicated and compared successfully across multiple laboratories.

Original languageEnglish (US)
Pages (from-to)4016-4023
Number of pages8
JournalCancer Research
Volume74
Issue number15
DOIs
StatePublished - Aug 1 2014
Externally publishedYes

Fingerprint Dive into the research topics of 'Enhancing reproducibility in cancer drug screening: How do we move forward?'. Together they form a unique fingerprint.

Cite this